內地審批放慢 7月僅3企准來港招股 傳中證監研提高市值門檻
《彭博》數據顯示,7月只有3家內地公司獲中國證監會批准,推進來港上市的計劃,數目創8個月以來最少。
報道提及,7月只有3家公司來港融資的計劃獲得中證監批准,是自去年11月以來,數量最少的一個月,6月時則有16家公司獲批。目前仍有許多公司欲來港上市,7月首3周已有逾50家在中證監備案。中證監網站顯示,目前有超過200家公司在排隊。
針對上述情況,中證監未有說明審批放慢的原因。但官媒《證券時報》周四報道,內地監管部門正考慮把赴港上市的A股公司市值門檻提高一倍,至200億元人民幣;並引述官員稱,目前已經遞表或公告將赴港的公司中,大多都符合這一標準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.